ENLV Company Profile and Key Details

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) closed at $1.16 USD, gaining $0.01 (0.87%) from the previous close of $1.15. The stock is currently mid-range between its 52-week high and low $0.66 and $2.10. With a market capitalization of about $28.19 million, Enlivex Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.59). Key stats such as the average daily volume over the past year has been around 554.73 thousand shares, volume is running light vs its 52-week average. Headquartered in Ness Ziona, None, Enlivex Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Oren Hershkovitz, the company employs approximately 71 people and listed since July 31, 2014. Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.

ENLV has shown mixed momentum, gaining 2.87% over the past week and -7.55% over the past quarter, though year-to-date performance is up 39.36%. Short-term trend indicators are mixed aligned (SMA20 4.69%, SMA50 18.13%, SMA200 7.41%). The stock’s 14-day RSI is 57.6 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.24% below its high and over 74.24% above its low. Average 10-day trading volume of 323.03 thousand shares is below the 3-month average of 553.52 thousand, indicating normal recent market interest.

Enlivex Therapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

Enlivex Therapeutics Ltd. generated EPS of -$0.53 over the past year. Five-year average earnings growth is 7.57%. Wall Street analysts project EPS growth of -6.39% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.09. Next year's EPS is expected at $36.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $7.00. The high target offers 1020.69% upside. The low target suggests 503.45% downside. The mean target is $12.00. This offers 934.48% upside. Enlivex Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended December 05, 2025, missed forecasts by 0.0%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in November 29, 2024.

Enlivex Therapeutics Ltd. has 23.85 million shares outstanding. The public float is 21.32 million shares, elevated short interest at 0.86% of float. This equals 196.54 thousand shares. The short ratio is 0.89 days. Institutional investors hold 11.44% of the float. Insiders own 4.61%.